3. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
FDA approval of Weltruza, a once-monthly schizophrenia injection, creates a fresh drug-launch catalyst. Investors can assess insurance coverage, prescribing adoption, competition, and the spending required to turn approval into revenue.
READ THIS: Teva Pharmaceutical (TEVA) Gets FDA Approval and a Fresh Shot at Growth
